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Sympathetic Nonadrenergic Transmission Contributes to
Autonomic Dysreflexia in Spinal Cord–Injured Individuals
Jan T. Groothuis, Gerard A. Rongen, Jaap Deinum, Peter Pickkers, A.H. Jan Danser,
Alexander C.H. Geurts, Paul Smits, Maria T.E. Hopman
Abstract—Autonomic dysreflexia is a hypertensive episode in spinal cord–injured individuals induced by exaggerated
sympathetic activity and thought to be -adrenergic mediated. -Adrenoceptor antagonists have been a rational first
choice; nevertheless, calcium channel blockers are primarily used in autonomic dysreflexia management. However,
-adrenoceptor blockade may leave a residual vasoconstrictor response to sympathetic nonadrenergic transmission
unaffected. The aim was to assess the -adrenergic contribution and, in addition, the role of supraspinal control to leg
vasoconstriction during exaggerated sympathetic activity provoked by autonomic dysreflexia in spinal cord–injured
individuals and by a cold pressure test in control individuals. Upper leg blood flow was measured using venous
occlusion plethysmography during supine rest and during exaggerated sympathetic activity in 6 spinal cord–injured
individuals and 7 able-bodied control individuals, without and with phentolamine (-adrenoceptor antagonist) and
nicardipine (calcium channel blocker) infusion into the right femoral artery. Leg vascular resistance was calculated. In
spinal cord–injured individuals, phentolamine significantly reduced the leg vascular resistance increase during
autonomic dysreflexia (85 versus 2413 arbitrary units; P0.04) in contrast to nicardipine (1510 versus 2413
arbitrary units; P0.12). In controls, phentolamine completely abolished the leg vascular resistance increase during a
cold pressure test (12 versus 1814 arbitrary units; P0.02). The norepinephrine increase during phentolamine
infusion was larger (P0.04) in control than in spinal cord–injured individuals. These results indicate that the leg
vascular resistance increase during autonomic dysreflexia in spinal cord–injured individuals is not entirely -adrenergic
mediated and is partly explained by nonadrenergic transmission, which may, in healthy subjects, be suppressed by
supraspinal control. (Hypertension. 2010;55:636-643.)
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Autonomic dysreflexia (AD) is a potentially life-threatening episodic hypertension that develops in 80%
to 90% of spinal cord–injured (SCI) individuals with a spinal
cord lesion at or above the sixth thoracic spinal segment
(T6).1 AD occurs in these SCI individuals because a large part
of the sympathetic nervous system is without central inhibi-
tory pathways.2,3 An arterial pressure increase is induced by
exaggerated sympathetic activity caused by visceral, noxious,
or nociceptive stimuli entering the spinal cord below the level
of the lesion and can be initiated by catheterization, bladder
distension, and bowel evacuation.1–4 AD is accompanied by
sweating, flushing, and a pounding headache1,4 and can lead
to severe morbidity and even mortality.5–8
Clinically, AD has been well documented, but the mecha-
nisms that mediate AD remain unclear.9 Because AD is induced
by exaggerated sympathetic activity, it is thought to be
-adrenergic mediated.2–4 Therapy with an -adrenoceptor
blocker has, therefore, been a rational first choice in AD
management.4 However, -adrenoceptor blockers may leave a
residual vasoconstrictor response to sympathetic cotransmit-
ters, such as adenosine triphosphate (ATP) and neuropeptide
Y, unaffected.10 These neurotransmitters may still cause a
vasoconstrictor response during -adrenoceptor blockade,
although their exact role during exaggerated sympathetic
activity is unclear. Because SCI individuals lack supraspinal
sympathetic control, their responses could differ from able-
bodied individuals in the contribution of nonadrenergic trans-
mission during exaggerated sympathetic reflexes. Nowadays,
a calcium channel blocker (nifedipine) is most commonly
used as a primary agent in the management of AD.4 A
calcium channel blocker may be useful to prevent or control
AD, indicated by a lower blood pressure response.11 How-
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ever, the effect of calcium channel blockers on the vasocon-
strictor response during AD is unknown.
The first aim was to assess the -adrenergic contribution to
leg vasoconstriction during AD in SCI individuals by
-adrenoceptor blockade. A second aim was to assess
whether an -adrenoceptor antagonist would be more effec-
tive than a calcium channel blocker in reducing the leg
vasoconstriction during AD. We hypothesized that an
-adrenoceptor antagonist would abolish the leg vasocon-
striction during AD and would, therefore, be more effective
than a calcium channel blocker. To test this hypothesis, the
effect of the -adrenoceptor antagonist phentolamine on leg
vasoconstriction during AD in SCI individuals was compared
with the calcium channel blocker nicardipine (intravenous
equivalent of nifedipine). The third aim was to assess the role
of the presence or absence of supraspinal control on sympa-
thetic nonadrenergic transmission during exaggerated sympa-
thetic activity by comparing the vascular responses of SCI
with those of control individuals. We hypothesized that the
contribution of -adrenergic receptor stimulation would be
more pronounced in SCI individuals. To test this hypothesis,
the effect of phentolamine on leg vasoconstriction during
exaggerated sympathetic activity in SCI, by means of AD,
was compared with control individuals by means of a cold
pressor test (CPT).
Methods
Subjects
Six male SCI individuals and 7 healthy male able-bodied control
individuals participated in this study (Table 1). All of the subjects
were normotensive (140/90 mm Hg; ausculatory blood pressure
measurement), free of overt cardiovascular diseases, and did not
report orthostatic hypotension. Two SCI and 2 control individuals
smoked and 4 SCI individuals used medication, none of which are
known to substantially interfere with vascular reactivity (rectal
laxantia [n2], furosemide, and tolterodine). All of the SCI individ-
uals had long-standing traumatic spinal cord injury with a motor and
sensory complete spinal cord lesion above T6 (American Spinal
Injury Association Impairment Scale A, zone of partial preservation
above T612). The level of spinal cord injury was assessed by clinical
examination. The study was carried out in accordance with the
Declaration of Helsinki and was approved by the medical ethical
committee of our institution. All of the subjects gave written
informed consent.
Experimental Procedures and Protocol
All of the subjects refrained from caffeine-containing food and
beverages, vitamin C supplements, nicotine, and alcohol for 12
hours before the experiment and from heavy physical activity for
24 hours before the experiment. Subjects had been fasting for 12
hours and had emptied their bladder in the hour before the experi-
ment. All of the experiments were performed in the morning in a
quiet, temperature-controlled room (231°C). Each subject was
studied on 2 different occasions, separated by 1 week. On the first
experimental day, subjects were screened with a health question-
naire, physical examination, and a resting ECG. Subsequently, a
measurement of leg vascular resistance (LVR) in supine rest and
during exaggerated sympathetic activity, that is, AD in SCI and a
CPT of the hand in control individuals. On the second experimental
day, nicardipine, a calcium ion influx inhibitor (calcium channel
blocker), and phentolamine, a nonselective competitive antagonist of
-adrenergic receptors, were successively infused into the right
femoral artery. LVR was measured during supine rest, as well as
during AD in SCI and during a CPT in control individuals.
On both days, subjects were positioned comfortably in a supine
position on a bed with an anti-ulcer mattress. Experimental proce-
dures on the first experimental day started after a supine resting
period of 30 minutes. First, baseline upper leg blood flow was
measured for 10 minutes in a supine position, and, subsequently, AD
was provoked in SCI individuals for 5 minutes. In control individ-
uals, a CPT of the hand was applied for 3 minutes, during which
upper leg blood flow was measured. On the second experimental
day, an intra-arterial cannula (Angiocath 16-gauge, Becton Dickin-
son Infusion Therapy Systems Inc) was introduced after local
anesthesia (0.4 mL of 10-mg/mL lidocaine hydrochloride, Fresenius
Kabi Nederland BV) using a modified Seldinger technique into the
right femoral artery at the level of the inguinal ligament for arterial
blood pressure measurement (HP monitor type 78353B, Hewlett
Packard GmbH) and intra-arterial drug administration by an auto-
matic syringe infusion pump (Type P2000, IVAC Medical Systems).
The measurements started after a supine resting period of 30
minutes after cannulation of the right femoral artery. First, baseline
upper leg blood flow was measured during a 5-minute saline (0.9%
NaCl, Baxter BV) infusion period, followed by nicardipine infusion
(1 mg/mL of Cardene, Astellas Pharma BV) for 10 minutes in a dose
of 0.5 g/min per 100 mL of leg volume.13,14 In a pilot study, higher
doses of nicardipine did not further increase blood flow in a control
individual. In the last 5 minutes of nicardipine infusion, AD was
provoked in SCI and a CPT in control individuals. After a resting
period of 30 minutes with only saline infusion, the same protocol
was performed but this time with phentolamine infusion (10 mg/mL
of Regitine, Novartis Pharma BV) in a dose of 12 g/min of 100 mL
of leg volume.15 Nicardipine was infused first because of the short
half-life time of 2 to 5 minutes,16 in contrast to the unclear half-life
time of phentolamine. The schedule of the protocol is shown in
Figure 1.
AD in SCI individuals was provoked by inflating a blood pressure
cuff to 220 mm Hg on the contralateral upper leg, which gives a
nociceptive stimulus.2,3 According to the literature, AD was achieved
when there was a systolic blood pressure response to the stimulus of
20 mm Hg3,17,18 or a 20% increase in blood pressure with visual-
ized vasoconstriction.4 On the first experimental day we attempted to
provoke AD with different stimuli (bladder percussion, CPT of the
foot, and inflating a blood pressure cuff) to see which stimulus would
Table 1. Subject Characteristics, Including the Specific
Characteristics of the SCI and Control Individuals
Subject
SCI
Level DOI, y Age, y
Height,
cm
Weight,
kg
SBP,
mm Hg
DBP,
mm Hg
SCI1 C5 17 46 181 105 130 78
SCI2 T5 28 46 198 65 108 78
SCI3 C7 45 69 179 81 108 60
SCI4 T5 10 39 178 70 106 62
SCI5 C7 34 52 182 92 108 62
SCI6 C7 12 36 183 58 110 50
SCI n6 442 1814 786 1123 654
C1 22 180 67 118 76
C2 34 194 110 124 90
C3 46 174 65 118 82
C4 26 188 73 128 64
C5 42 188 88 118 78
C6 29 180 76 136 70
C7 54 187 85 138 70
Control n7 364 1842 815 1263* 763
Values represent meanSD. DOI indicates duration of injury; C in column 1
indicates control subjects; SBP, systolic blood pressure; DBP, diastolic blood
pressure; C, cervical spinal segment; T, thoracic spinal segment.
*Data are significantly different from SCI.
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result in the highest increase in blood pressure and fulfill the
criteria.3,4,17,18 Bladder percussion could not be performed in all of
the SCI individuals (sacral rhizotomy and electric bladder stimula-
tor), and the frequency and pressure of the bladder percussion was
difficult to standardize. A CPT of the foot did not increase mean
arterial pressure (MAP) in 5 consecutive SCI individuals and was,
therefore, considered an inappropriate stimulus. Inflating a blood
pressure cuff to 220 mm Hg on the contralateral leg resulted in the
highest increases in blood pressure, was consistent in provoking AD,
appeared easy to standardize, and was applicable for each SCI
individual. Inflating a blood pressure cuff to 220 mm Hg did not
result in hemodynamic changes or in LVR of the contralateral leg in
control individuals. We, therefore, decided to use this stimulus to
provoke AD in SCI individuals.
To elevate sympathetic activity in control individuals, a CPT of
the hand was applied.19 A CPT consisted of immersion of the right
hand into ice-water (4°C) for a period of 3 minutes.19
Measurements
Bilateral upper leg blood flow was measured by ECG-triggered
venous occlusion plethysmography, using mercury-in-silastic strain
gauges (DE Hokanson, Bellevue, WA), and electrically calibrated.20
In the supine position, the legs were positioned 5 cm above heart
level to facilitate venous outflow between venous occlusions.21
Strain gauges were placed 10 cm above the patella, and 12-cm width
occlusion cuffs, placed on the thigh above the strain gauge, were
inflated with a rapid cuff inflator (DE Hokanson), within 1 second,
to 50 mm Hg.22 Occlusion pressures were sustained for 8 heart
cycles, after which the cuff was deflated instantaneously (for 10
heart cycles).
Arterial blood pressure was measured continuously using a non-
invasive blood pressure device (Portapres, TNO) on day 1. A finger
cuff was attached to the middle phalanx of the left third finger to
measure finger arterial blood pressure, which accurately reflects
intra-arterial blood pressure changes.23 On day 2, arterial blood
pressure was continuously measured intra-arterially using the femo-
ral artery cannula. MAP values were derived beat to beat, and heart
rate was the inverse of the interbeat interval.
Leg volume was determined by anthropometry, as described and
validated by Jones and Pearson.24
Venous (day 1) and arterial (day 2) blood samples were taken to
determine norepinephrine levels in SCI and control individuals. In
SCI individuals, renin and angiotensin II levels were determined as
well to establish a possible role of the renin-angiotensin system in
AD. The blood samples were taken at rest, before infusion of
nicardipine and phentolamine, and directly after AD in SCI and after
a CPT in control individuals (Figure 1). The samples were collected
in prechilled glass tubes on melting ice containing glutathione and
EDTA for determination of norepinephrine levels and nonchilled
glass tubes for determination of renin and angiotensin II levels.
Samples were processed immediately in a refrigerated centrifuge and
stored at 80°C until further analysis. Plasma norepinephrine was
measured by sensitive and specific high-performance liquid chroma-
tography with fluorometric detection, as described previously.25
Plasma renin was measured by immunoradiometric assay provided
by CISbio International, and angiotensin II levels in medium were
measured by radioimmunoassay (detection limit: 0.5 pmol/L) as
described previously.26
Data Analysis
A data acquisition system digitalized the data with a sample frequency
of 100 Hz (Medical Information Data Acquisition, Instrumentation
Department, Radboud University Nijmegen Medical Centre). Upper leg
blood flow was calculated as the slope of the volume change over a
4-second interval using a customized computer program (MATLAB
6.1, Mathworks). MAP and heart rate values over the same intervals
were averaged.
LVR was calculated as the arterial-venous pressure gradient
divided by upper leg blood flow. For these calculations, we assumed
that central venous pressure was 9 mm Hg in a supine position.27
During AD and during a CPT, the average of the highest 3
consecutive measurements was taken to determine LVR.
Statistical Analysis
Statistical analyses were performed using SPSS 16.0 (SPSS) soft-
ware. Data are presented as meanSD unless otherwise stated. The
level of statistical significance was set at 0.05. To assess
differences in baseline values between SCI and control individuals,
unpaired t tests were used. Repeated-measures ANOVAs were used
to assess the effect of AD within the SCI group and of a CPT within
the control group on the first day and the effect of infusion of
nicardipine or phentolamine on the second day. Post hoc t tests were
performed when the ANOVA reported a significant main or inter-
action effect. Bonferroni correction was used to correct for multiple
comparisons.
Results
Baseline Values
Supine resting systolic blood pressure and MAP in SCI were
lower (P0.02) and LVR was higher (P0.01) compared
with control individuals. Provoking AD in SCI and perform-
ing a CPT in control individuals on day 1 resulted in an
Day 2: invasive measurement
PhentolamineNicardipine SalineSaline
-30 0                  5 10 15 45 50 55 60 min
Supine SupineAD/CPT AD/CPT
cannulation arterial blood samples
Day 1: non-invasive measurement
Supine AD/CPT
venous blood samples
0                  5 10 min
arterial blood samples
Figure 1. Schematic representation of the experimental protocol. AD indicates autonomic dysreflexia in SCI individuals. CPT indicates
cold pressor test of the hand in control individuals. Saline, NaCl 0.9%; nicardipine, 0.5 g/min per 100 mL of leg volume; phentol-
amine, 12 g/min per 100 mL of leg volume.
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increase in MAP (P0.01 and P0.01, respectively) and
LVR (P0.01 and P0.01, respectively), whereas heart rate
did not change in either group. The LVR increase during AD
in SCI was similar to the increase during a CPT in control
individuals (Tables 1 through 3 and Figure 2).
Phentolamine and Nicardipine Infusion During AD
in SCI Individuals
LVR in SCI individuals was lower (P0.02) during saline
infusion on day 2 compared with the baseline value on day 1.
Infusion of phentolamine did not change MAP and heart rate
but did lower LVR (P0.04). Provoking AD during phen-
tolamine infusion did not change MAP and heart rate;
however, LVR increased (P0.02). The increase in LVR was
significantly lower (P0.04) during phentolamine infusion
(8.04.5 arbitrary units [AU]) compared with the LVR
increase on day 1 (23.613.4 AU). Nicardipine infusion did
not change MAP, heart rate, or LVR. Provoking AD during
nicardipine infusion resulted in an increase in MAP (P0.03)
and LVR (P0.04) with no change in heart rate. The increase
Table 2. Systemic Hemodynamic Variables and LVR Reactions During AD in SCI Individuals and CPT in
Control Individuals Without and With Phentolamine or Nicardipine Infusion
Intervention
SCI Individuals (n6) Control Individuals (n7)
MAP, mm Hg HR, bpm LVR, AU MAP, mm Hg HR, bpm LVR, AU
Baseline 826 557 32.73.1 966‡ 576 22.36.6‡
AD/CPT 1038* 526 56.313.8* 11214* 596 40.117.8*
Phentolamine infusion
Saline 779 5110 23.87.2 9013 617 21.95.7
Phentolamine 7512 5410 18.96.2* 8611 668* 12.41.9*
AD/CPT 8411 5310 26.98.2† 913 684 13.12.5
Nicardipine infusion
Saline 7910 5311 23.66.3 8612 577 19.85.5
Nicardipine 7811 5311 21.36.0 8511 628* 13.84.1*
AD/CPT 9011† 5110 36.415.5† 9413† 654 18.17.3†
Values represent meanSD. HR indicates heart rate.
*Data are significantly different from baseline or saline.
†Data are significantly different from nicardipine or phentolamine.
‡Data are significantly different from SCI individuals.
Table 3. Individual Increase in MAP and LVR During AD in SCI Individuals and CPT in Control Individuals Without and With
Phentolamine or Nicardipine Infusion
Subject
Day 1 Phentolamine Infusion Nicardipine Infusion
 MAP, mm Hg (%)  LVR, AU (%)  MAP, mm Hg (%)  LVR, AU (%)  MAP, mm Hg (%)  LVR, AU (%)
SCI during AD
SCI1 12 (13) 4 (13) 2 (2) 14 (87) 8 (8) 9 (57)
SCI2 15 (16) 43 (142) 4 (4) 3 (16) 9 (10) 9 (50)
SCI3 33 (44) 20 (54) 8 (12) 9 (30) 17 (25) 21 (72)
SCI4 6 (8) 19 (67) 1 (2) 10 (64) 4 (5) 24 (101)
SCI5 30 (40) 33 (95) 36 (58) 11 (58) 27 (39) 25 (98)
SCI6 29 (36) 22 (67) 3 (4) 3 (14) 8 (11) 2 (12)
SCI (n6) 2111 (2615) 2413 (7340) 913* (1422) 85* (4527) 128* (1613) 159† (6530)
Control during CPT
C1 4 (5) 7 (51) 8 (10) 1 (9) 13 (16) 11 (58)
C2 14 (15) 8 (54) 15 (14) 3 (23) 13 (12) 5 (27)
C3 9 (9) 12 (41) 6 (7) 3 (26) 3 (4) 1 (13)
C4 6 (6) 14 (54) 10 (13) 2 (19) 2 (3) 1 (8)
C5 15 (15) 17 (58) 6 (7) 0 (3) 6 (7) 1 (10)
C6 34 (36) 47 (175) 14 (19) 0 (3) 16 (21) 10 (82)
C7 31 (32) 21 (110) 7 (9) 0 (4) 13 (16) 1 (14)
Control (n7) 1612 (1712) 1813 (7845) 59* (710) 12* (614) 96* (108) 44* (3026)
Values represent meanSD.  indicates increase; %, percentage increase; C, control subject.
*Data are significantly different from day 1.
†Data are significantly different from phentolamine infusion.
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in MAP during AD was significantly lower (P0.03) during
nicardipine infusion (11.98.4 mm Hg) compared with the
MAP increase on day 1 (21.310.9 mm Hg). Nicardipine did
not significantly attenuate the LVR increase during AD
(P0.12), whereas the LVR increase provoked by AD was
significantly lower (P0.05) during phentolamine (8.04.5
AU) compared with nicardipine infusion (15.19.9 AU). In
the noninfused leg, no change in LVR was seen during
infusion of phentolamine (31.310.3 versus 30.010.0 AU)
or during nicardipine (33.015.8 versus 33.816.8 AU;
Tables 2 and 3 and Figure 2).
Phentolamine and Nicardipine During CPT in
Control Individuals
Phentolamine infusion in control individuals did not change
MAP but did increase heart rate (P0.02) and resulted in a
decrease in LVR (P0.01). Phentolamine infusion com-
pletely abolished the LVR increase in response to a CPT
without affecting MAP or heart rate. Infusion of nicardipine
did not change MAP but increased heart rate (P0.02) and
decreased LVR (P0.05) in control individuals. A CPT
during nicardipine infusion increased MAP and LVR
(P0.04 and P0.03, respectively) with no change in heart
rate. The MAP and LVR increase were significantly less
pronounced (P0.04 and P0.03, respectively) during
nicardipine infusion compared with day 1. In the noninfused
leg, no change in LVR was seen during phentolamine
infusion (23.08.6 versus 21.18.0 AU), and the LVR
increase during a CPT to 27.211.9 AU was lower compared
with day 1, probably because of spillover of phentolamine to
the noninfused leg. LVR in the noninfused leg did not change
during nicardipine infusion (21.17.6 versus 21.88.0 AU),
and during a CPT, the LVR increased (37.216.0 AU)
similar to day 1 (Tables 2 and 3 and Figure 2).
Blood Samples
Baseline norepinephrine levels were significantly lower
(P0.01) in SCI compared with control individuals. During
AD, norepinephrine did not significantly increase in SCI in
contrast to control individuals during a CPT (P0.01).
Norepinephrine increased significantly during AD, in combi-
nation with phentolamine and nicardipine infusion in SCI
(P0.04 and P0.03, respectively) and during a CPT in
control individuals (P0.01, both conditions). The increase
in norepinephrine during phentolamine infusion was signifi-
cantly more pronounced (P0.04) in control than in SCI
individuals. There were no significant increases in renin and
angiotensin II levels during AD in SCI individuals without or
with phentolamine or nicardipine infusion (Table 4).
Discussion
The major finding of this study is that AD in SCI individuals
is not entirely mediated through the -adrenergic pathway,
indicated by the presence of a remaining residual leg vaso-
constrictor response during AD in SCI individuals during
phentolamine infusion. Nevertheless, a more pronounced
attenuation of the LVR increase during AD was present
during phentolamine infusion compared with a nicardipine
infusion. In contrast to SCI individuals, phentolamine infu-
sion completely abolished the vasoconstriction response to a
CPT in control individuals, which could indicate that the
presence of supraspinal sympathetic control in control indi-
viduals may suppress the role of nonadrenergic transmission
during exaggerated sympathetic activity.
0
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Figure 2. LVR in SCI individuals (n6, top graph) and control
individuals (n7, bottom graph). During supine rest, infusion of
phentolamine and nicardipine and during autonomic dysreflexia
in SCI and CPT in control individuals with and without infusion.
Values represent meanSE. *Significant difference.
Table 4. Norepinephrine, Renin, and Angiotensin II Levels
at Baseline and During AD in SCI Individuals and a CPT in
Control Individuals Without and With Phentolamine or
Nicardipine Infusion
Intervention
SCI Individuals (n6)
Control
(n7), NE,
nmol/L
NE,
nmol/L
Renin,
mE/L
AT II,
pmol/L
Baseline 0.660.31 105 1.961.00 1.090.18†
AD/CPT 0.930.21 107 2.021.38 1.930.71*†
Phentolamine infusion
Saline 0.760.74 94 1.200.32 1.140.29
AD/CPT 1.491.44* 94 1.460.58 3.221.11*
Nicardipine infusion
Saline 0.600.60 75 1.340.65 0.900.15
AD/CPT 1.000.92* 75 0.960.47 1.670.41*
Values represent meanSD. Control, control individuals; NE, norepineph-
rine; AT II, angiotensin II; AD/CPT, autonomic dysreflexia in SCI individuals or
CPT in control individuals.
*Data are significantly different from baseline or saline.
†Data are significantly different from SCI individuals.
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Contribution of Nonadrenergic Transmission
The LVR increase during AD in SCI individuals did not
differ from the LVR increase during a CPT in control
individuals. Nevertheless, phentolamine completely abol-
ished the LVR increase in control individuals during a CPT,
whereas a significant residual leg vasoconstrictor response
occurred in SCI individuals during AD with phentolamine
infusion. These results suggest that nonadrenergic transmis-
sion contributes to the leg vasoconstriction during exagger-
ated sympathetic activity in SCI but not in control individu-
als. This interpretation is supported by the more pronounced
increase in plasma norepinephrine levels in control individ-
uals compared with SCI individuals in response to exagger-
ated sympathetic activity. This observation challenges the
widespread view that the vasoconstrictor response during AD
in SCI individuals is entirely -adrenergic mediated.2–4,28
Because phentolamine is a nonselective competitive
-adrenoceptor antagonist, incomplete -adrenoceptor block-
ade could, in theory, explain the residual LVR increase in SCI
individuals. A similar intra-arterial dose of phentolamine has
been used previously and achieved a maximal vasodilator
effect in both SCI and control individuals, indicating com-
plete -adrenoceptor blockade.15,29,30 Moreover, the LVR
increase during a CPT in control individuals was completely
abolished during phentolamine infusion, despite a larger
increase in plasma norepinephrine compared with SCI indi-
viduals. This confirms that intra-arterial infusion of phentol-
amine achieved effective intrasynaptic drug concentrations30
and excludes incomplete -adrenergic blockade as an expla-
nation for the residual vasoconstrictor response in SCI indi-
viduals in the present study.
Because vasoconstriction during AD occurs rapidly, it is
not likely that other vasoconstrictor mechanisms play an
important role, such as the renin-angiotensin system. The
renin-angiotensin system is a slow-acting vasoconstriction
mechanism and, therefore, unlikely to cause immediate arte-
rial vasoconstriction on a visceral, noxious, or nociceptive
stimulus. Moreover, there were no increases in renin and
angiotensin II levels during AD in SCI individuals, support-
ing the notion that there was no activation of the renin-an-
giotensin system. However, the local angiotensin system
could still play a role, because we did not have an additional
angiotensin II subtype I receptor blockade. It is unlikely that
vasopressin plays a role, because vasopressin levels are low
in SCI individuals and do not increase during AD.31 The
instant reaction to the triggering stimulus provoking AD in
combination with the lack of supraspinal control in SCI
individuals causing exaggerated sympathetic activity pro-
vides enough evidence for a sympathetic-mediated mecha-
nism. Because -adrenoceptor blockade did not abolish the
LVR increase during AD, other sympathetic neurotransmit-
ters might be involved, such as ATP and neuropeptide Y.10
ATP, neuropeptide Y, and norepinephrine are costored in the
sympathetic synapse and are simultaneously released.32 Re-
ceptors for these neurotransmitters are located on smooth
muscle and endothelial cells of blood vessels.32 It is thought
that norepinephrine and ATP have a coordinated action in
neurogenic vasoconstriction, which is modulated by neu-
ropeptide Y.32 We did not investigate the mechanism by
which spinal cord injury increases sympathetic nonadrenergic
transmission. Because the sympathetic nervous system below
the lesion in SCI individuals is without central inhibitory
pathways,2,3 in contrast to control individuals, we speculate
that an intact supraspinal control of sympathetic outflow
preferentially suppresses sympathetic nonadrenergic trans-
mission. Alternatively, spinal cord injury alters the relative
concentrations of costored neurotransmitters. In this regard,
an intermediate role for endothelin is worth mentioning. We
have shown previously that the contribution of endothelin in
LVR is increased in SCI individuals.33 In rats, endothelin 1
infusion increased the relative contribution of ATP as a
functional sympathetic neurotransmitter.34 Therefore, endo-
thelin may mediate the increased contribution of nonadren-
ergic neurogenic vasoconstriction in SCI individuals.
Phentolamine Effect Superior to Nicardipine
Provoking AD in SCI individuals during nicardipine infusion
still resulted in an LVR increase with a concurrent increase in
MAP. However, the MAP increase with nicardipine infusion
was lower compared with day 1, indicating an attenuation of
the blood pressure response during AD in SCI individuals. This
is consistent with 1 previous study demonstrating a lower blood
pressure response during oral nifedipine pretreatment in SCI
individuals who exhibited AD during electroejaculation.11 How-
ever, the LVR increase was similar to day 1, indicating a minor
effect of nicardipine on leg vasoconstriction.
Despite the residual LVR increase during AD in SCI
individuals with phentolamine infusion, this LVR increase
was significantly lower than with nicardipine infusion, and,
moreover, with phentolamine there was no change in MAP.
These results indicate a superior effect of an -adrenoceptor
antagonist compared with a calcium channel blocker on leg
vasoconstriction and concurrent blood pressure response
during AD in SCI individuals.
An obvious explanation for the observed difference in
effect could be an inefficient dosage of nicardipine. Infusion
of nicardipine did not result in a significant decrease in basal
LVR in SCI individuals. However, in control individuals,
basal LVR decreased with the same dose, and, in a pilot
study, higher dosages of nicardipine did not result in a more
pronounced vasodilatory effect. We are, therefore, convinced
that we used a sufficient dose of nicardipine. The vasodila-
tation caused by nicardipine is, however, more pronounced in
hypertensive compared with normotensive individuals.16 Be-
cause blood pressure in SCI individuals was lower compared
with control individuals, the effect of nicardipine on LVR
could be smaller for this reason.
Baseline Values
Consistent with our results, SCI individuals with a high spinal
cord lesion are prone to low resting blood pressures,1–3 which
is thought to be attributed to a diminution in sympathetic
nervous activity below the lesion as supported by low plasma
norepinephrine levels.1,2 Although the reduced norepineph-
rine levels in SCI individuals may also be influenced by the
efficiency of the reuptake by the norepinephrine transporter
and changes in blood flow redistribution caused by inactivity
and muscle atrophy. Despite lower sympathetic activity, SCI
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individuals have a higher resting LVR,15,30,35 probably be-
cause of a combination of functional33 and structural vascular
changes.36 During AD, SCI individuals can increase their
LVR to the same extent as control individuals during a CPT.
Although a CPT is not directly comparable with AD, both are
strong sympathetic stimuli, notwithstanding the physiological
and neurological differences, especially the absence (SCI) or
presence (control) of supraspinal control.2,3
Limitations
Although -adrenergic responsiveness deteriorates with
age,37,38 all of the SCI and control individuals demonstrated
similar increases in LVR during AD and a CPT, respectively,
compared with their peers. Moreover, the oldest control
individual (C7, 54 years) had a complete abolished LVR
increase during a CPT with phentolamine infusion, and the
oldest SCI individual (SCI3, 69 years) had an attenuated LVR
increase during AD with phentolamine infusion.
Infusion of saline in SCI individuals lowered supine LVR
compared with day 1. This is probably because of a more
pronounced reaction to an increase in shear on the vascular
wall, caused by the saline infusion, because of functional
changes in SCI individuals.33 The noninfused leg did not
demonstrate a lower supine LVR, indicating that the lower
supine LVR in the infused leg is probably caused by the
saline infusion. The lower supine LVR did not have any
effect on MAP and heart rate. Because the focus of the study
was the effect of phentolamine and nicardipine infusion on
the LVR increase during AD and a CPT, we may assume that
the lower basal LVR did not influence our results.
Perspectives
The management of AD in SCI individuals remains a chal-
lenge in clinical practice.18,39 Over the years, many different
antihypertensive agents have been used.4,18 In earlier days,
-adrenoceptor antagonists were used4; however, their use
was limited, and nowadays nifedipine (calcium channel
blocker) is used as a primary agent in the management of
AD.4 However, the present study demonstrates that an
-adrenoceptor antagonist appears to have a more pro-
nounced effect than a calcium channel blocker on the LVR
and concurrent MAP increase during AD in SCI individuals.
Moreover, serious adverse reactions after the use of
immediate-release nifedipine in hypertensive emergencies in
non-SCI individuals have been reported.40 The present study
demonstrates that AD in SCI individuals is not entirely
-adrenergic mediated and that sympathetic nonadrenergic
transmission may partly explain the LVR increase. The
development of antagonists of nonadrenergic transmitters
may be a target for future AD management in SCI individu-
als. Perhaps these antagonists may reduce the blood pressure
increase during AD without lowering the blood pressure in
the absence of AD.
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